Skip to main content

Table 2 Summary of c-DMARDs and b-DMARDs prescribed in the cohort

From: Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study

 

Persistent oligoarticular JIA (n = 78)

Extended oligoarticular JIA (n = 56)

Polyarticular JIA RF- (n = 103)

Polyarticular JIA RF + (n = 26)

ERA (n = 62)

Total (n = 325)

c-DMARD

 Number of distinct c-DMARD prescribed (n, %)

  0

40 (51%)

6 (11%)

0 (0%)

0 (0%)

7 (11%)

53 (16%)

  1

32 (41%)

37 (66%)

65 (63%)

16 (62%)

38 (62%)

188 (58%)

   ≥ 2

6 (8%)

13 (23%)

37 (37%)

10 (38%)

17 (27%)

84 (26%)

 c-DMARD types (n, %)

  Methotrexate

34 (44%)

45 (80%)

99 (96%)

26 (100%)

39 (63%)

243 (75%)

  Sulfasalazine

 < 5 (< 6%)

7 (12%)

21 (20%)

 < 5 (< 19%)

30 (48%)

66 (20%)

  HCQ

5 (6%)

6 (11%)

16 (16%)

6 (23%)

 < 5 (< 8%)

36 (11%)

  Leflunomide

 < 5 (< 6%)

6 (11%)

13 (13%)

 < 5 (< 19%)

 < 5 (< 8%)

26 (8%)

 c-DMARD therapy combination

  Double c-DMARD

5 (6.4%)

8 (14%)

27 (26%)

9 (35%)

12 (19%)

61 (19%)

  Triple c-DMARD

0

 < 5 (< 9%)

 < 5 (< 5%)

 < 5 (< 19%)

0

5 (2%)

b-DMARD

 Number of distinct b-DMARD prescribed (n, %)

  0

69 (88%)

31 (55%)

40 (39%)

8 (31%)

30 (48%)

178 (55%)

  1

9 (12%)

22 (39%)

46 (45%)

13 (50%)

21 (34%)

111 (34%)

   ≥ 2

0

 < 5 (< 9%)

17 (16%)

5 (19%)

11 (18%)

36 (11%)

 b-DMARD types (n, %)

  Etanercept

 < 5 (< 6%)

14 (25%)

44 (43%)

15 (58%)

25 (40%)

102 (31%)

  Adalimumab

 < 5 (< 6%)

9 (16%)

21 (20%)

 < 5 (< 19%)

13 (21%)

51 (16%)

  Tocilizumab

 < 5 (< 6%)

 < 5 (< 9%)

11 (11%)

 < 5 (< 19%)

 < 5 (< 8%)

17 (5%)

  Othersa

0

 < 5 (< 9%)

13 (13%)

 < 5 (< 19%)

10 (16%)

28 (9%)

  1. JIA Juvenile idiopathic arthritis, RF Rheumatoid factor negative, RF Rheumatoid factor positive, ERA Enthesis-related arthritis, c-DMARD Conventional disease anti-rheumatic drugs, b-DMARD Biologic disease anti-rheumatic drugs, HCQ Hydroxychloroquine
  2. aGolimumab, infliximab, tofacitinib, abatacept, and secukinumab